221 related articles for article (PubMed ID: 30084057)
21. Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure.
Sagnelli E; Starace M; Minichini C; Pisaturo M; Macera M; Sagnelli C; Coppola N
Infection; 2018 Dec; 46(6):761-783. PubMed ID: 30084057
[TBL] [Abstract][Full Text] [Related]
22. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals.
Coppola N; Minichini C; Starace M; Sagnelli C; Sagnelli E
J Med Virol; 2016 Oct; 88(10):1659-71. PubMed ID: 26991255
[TBL] [Abstract][Full Text] [Related]
23. Resistance Associated Mutations in HCV Patients Failing DAA Treatment.
Di Stefano M; Faleo G; Farhan Mohamed AM; Morella S; Bruno SR; Tundo P; Fiore JR; Santantonio TA
New Microbiol; 2021 Jan; 44(1):12-18. PubMed ID: 33453702
[TBL] [Abstract][Full Text] [Related]
24. Direct acting antivirals failure: cause and retreatment options.
Parlati L; Pol S
Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1245-1250. PubMed ID: 30791789
[TBL] [Abstract][Full Text] [Related]
25. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS].
Gozlan Y; Mendelson E; Ben-Ari Z; Mor O
Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C virus resistance to the new direct-acting antivirals.
Esposito I; Trinks J; Soriano V
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1197-209. PubMed ID: 27384079
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.
Sorbo MC; Cento V; Di Maio VC; Howe AYM; Garcia F; Perno CF; Ceccherini-Silberstein F
Drug Resist Updat; 2018 Mar; 37():17-39. PubMed ID: 29525636
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.
Asselah T; Reesink H; Gerstoft J; de Ledinghen V; Pockros PJ; Robertson M; Hwang P; Asante-Appiah E; Wahl J; Nguyen BY; Barr E; Talwani R; Serfaty L
Liver Int; 2018 Sep; 38(9):1583-1591. PubMed ID: 29461687
[TBL] [Abstract][Full Text] [Related]
29. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Zeuzem S; Foster GR; Wang S; Asatryan A; Gane E; Feld JJ; Asselah T; Bourlière M; Ruane PJ; Wedemeyer H; Pol S; Flisiak R; Poordad F; Chuang WL; Stedman CA; Flamm S; Kwo P; Dore GJ; Sepulveda-Arzola G; Roberts SK; Soto-Malave R; Kaita K; Puoti M; Vierling J; Tam E; Vargas HE; Bruck R; Fuster F; Paik SW; Felizarta F; Kort J; Fu B; Liu R; Ng TI; Pilot-Matias T; Lin CW; Trinh R; Mensa FJ
N Engl J Med; 2018 Jan; 378(4):354-369. PubMed ID: 29365309
[TBL] [Abstract][Full Text] [Related]
30. Virological patterns of HCV patients with failure to interferon-free regimens.
Starace M; Minichini C; De Pascalis S; Macera M; Occhiello L; Messina V; Sangiovanni V; Adinolfi LE; Claar E; Precone D; Stornaiuolo G; Stanzione M; Ascione T; Caroprese M; Zampino R; Parrilli G; Gentile I; Brancaccio G; Iovinella V; Martini S; Masarone M; Fontanella L; Masiello A; Sagnelli E; Punzi R; Salomone Megna A; Santoro R; Gaeta GB; Coppola N
J Med Virol; 2018 May; 90(5):942-950. PubMed ID: 29315640
[TBL] [Abstract][Full Text] [Related]
31. Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Poordad F; Pol S; Asatryan A; Buti M; Shaw D; Hézode C; Felizarta F; Reindollar RW; Gordon SC; Pianko S; Fried MW; Bernstein DE; Gallant J; Lin CW; Lei Y; Ng TI; Krishnan P; Kopecky-Bromberg S; Kort J; Mensa FJ
Hepatology; 2018 Apr; 67(4):1253-1260. PubMed ID: 29152781
[TBL] [Abstract][Full Text] [Related]
32. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
33. Retreatment With Sofosbuvir Plus Grazoprevir/Elbasvir Plus Ribavirin of Patients With Hepatitis C Virus Genotype 1 or 4 Who Previously Failed an NS5A- or NS3-Containing Regimen: The ANRS HC34 REVENGE Study.
de Lédinghen V; Laforest C; Hézode C; Pol S; Renault A; Alric L; Larrey D; Métivier S; Tran A; Jézéquel C; Samuel D; Zoulim F; Tual C; Pailhé A; Gibowski S; Bourlière M; Bellissant E; Pawlotsky JM
Clin Infect Dis; 2018 Mar; 66(7):1013-1018. PubMed ID: 29077864
[TBL] [Abstract][Full Text] [Related]
34. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor.
Lawitz E; Yang JC; Stamm LM; Taylor JG; Cheng G; Brainard DM; Miller MD; Mo H; Dvory-Sobol H
Antivir Ther; 2018; 23(4):325-334. PubMed ID: 29063860
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
